echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The first CAR-T in China is coming! Fosun Kate Aquilonsai injections are about to be approved

    The first CAR-T in China is coming! Fosun Kate Aquilonsai injections are about to be approved

    • Last Update: 2021-03-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 12, NMPA's official website showed that fosun Kate CAR-T product "Aquilonsai Injection" market application (acceptance number: CXSS2000006) entered the administrative approval stage, is expected to be approved in the nearth.
    this means that the first CAR-T therapeutic products are about to be approved for sale!From NMPA's official website, Aquilonsai Injection, codentag FKC876, Fosun Kate introduced YESCARTA (Axicabtagene Ciloleucel) technology from Kite Pharma in the United States and is authorized to localize the production of targeted CD19 self-contained CAR-T cell therapy products in China.
    October 18, 2017, Yescarta was approved by the FDA to treat patients with recurring and incurable large B-cell lymphoma, the first FDA-approved CAR-T cell drug for specific non-Hodgkin's lymphoma.
    27 August 2018, it was approved for listing in Europe for the treatment of relapsed or resecurable DLBCL and PMBCL.
    currently has three approved CAR-T cell immunotherapy products on the market worldwide, including Kite Pharmaceuticals' Yescarta and Tecartus and Novarma's Kymriah, all targeting CD19.
    details of its approval time and adaptation are as follows: According to Gilead and Novartic's published financial reports, Yescarta and Kymriah's global sales for fiscal 2019 were approximately $456 million and $278 million, respectively.
    Fosun Kate introduced Yescarta from Kite Pharma in the United States in early 2017 to gain technical and commercial rights in Chinese mainland, the Hong Kong Special Administrative Region and the Macao Special Administrative Region, and intends to localize production in China.
    august 2018, the CDE approved its IND application, and in February 2020 Fosun Kate submitted a listing application, which took just over a year.
    February 21, 2020, Fosun Kate Aquilonsai's application for the market for injections was accepted by the National Drug Administration (NMPA).
    's listing application is based on a one-arm, open, multi-center bridging clinical trial (FKC876-2018-001) conducted in China to assess the safety and efficacy of this product in chinese patients with refratic invasive NHL (Large B cell lymphoma).
    10, 2020, the listing application was formally approved by the CDE for priority review.
    the drug entered the administrative approval stage today.
    to be approved by the company in less than a year.
    Aquilonsai Injection Review Time Axis from the Insight database () Insight database shows that, in addition to Fosun Kate, only the CAR-T products of the Pharmaceutical Ming Juno family are currently on the market.
    car-T products in the clinical phase, Novart's Kymriah® (tisagenlecleucel) is the fastest-growing, with Phase III clinical start-ups and seven domestic CAR-T products already in Phase II clinical.
    , it is worth mentioning that nanjing's legendary BCMA Targeted CAR-T was incorporated into the breakthrough therapy program by CDE in August 2020.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.